Agenda

The conditions that drive the highest long-term costs for payers and employers - cardiovascular disease, cognitive decline, hospitalisation - share a common and consistently overlooked upstream risk factor: lung health. Women with undiagnosed or undertreated pulmonary disease face a significantly elevated risk of cardiovascular events within six months of a respiratory episode. Lung function begins declining at perimenopause, yet it rarely features in women's health benefit design, screening protocols or risk stratification models used by payers and employers today. This session makes the economic case for integrating lung health into women's preventive care frameworks, exploring: ' How undiagnosed lung disease accelerates cardiovascular and neurological risk, creating downstream cost exposure payers and employers are not yet accounting for. ' Why the menopausal visit represents one of the most significant missed screening opportunities in women's preventive health. ' What the emerging biologics and monitoring pipeline looks like, and how the commercial landscape for lung health in women is beginning to shift. ' How payers and employers can begin evaluating lung health within existing women's health benefit frameworks.